252 related articles for article (PubMed ID: 25310526)
1. +TIP EB1 downregulates paclitaxel‑induced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules.
Thomas GE; Sreeja JS; Gireesh KK; Gupta H; Manna TK
Int J Oncol; 2015 Jan; 46(1):133-46. PubMed ID: 25310526
[TBL] [Abstract][Full Text] [Related]
2. End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability.
Luo Y; Li D; Ran J; Yan B; Chen J; Dong X; Liu Z; Liu R; Zhou J; Liu M
Protein Cell; 2014 Jun; 5(6):469-79. PubMed ID: 24748116
[TBL] [Abstract][Full Text] [Related]
3. Depletion of end-binding protein 1 (EB1) promotes apoptosis of human non-small-cell lung cancer cells via reactive oxygen species and Bax-mediated mitochondrial dysfunction.
Kim MJ; Yun HS; Hong EH; Lee SJ; Baek JH; Lee CW; Yim JH; Kim JS; Park JK; Um HD; Hwang SG
Cancer Lett; 2013 Oct; 339(1):15-24. PubMed ID: 23900080
[TBL] [Abstract][Full Text] [Related]
4. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity.
Sun X; Li D; Yang Y; Ren Y; Li J; Wang Z; Dong B; Liu M; Zhou J
J Pathol; 2012 Mar; 226(4):666-73. PubMed ID: 21989536
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway.
Zhang W; Cai J; Chen S; Zheng X; Hu S; Dong W; Lu J; Xing J; Dong Y
Mol Med Rep; 2015 Jul; 12(1):1506-14. PubMed ID: 25760096
[TBL] [Abstract][Full Text] [Related]
6. Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells.
Choi YH; Yoo YH
Oncol Rep; 2012 Dec; 28(6):2163-9. PubMed ID: 23023313
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
Promkan M; Liu G; Patmasiriwat P; Chakrabarty S
Int J Cancer; 2009 Dec; 125(12):2820-8. PubMed ID: 19551867
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic function of microtubule end-binding protein 1 in breast cancer.
Dong X; Liu F; Sun L; Liu M; Li D; Su D; Zhu Z; Dong JT; Fu L; Zhou J
J Pathol; 2010 Feb; 220(3):361-9. PubMed ID: 19967727
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
Sui M; Huang Y; Park BH; Davidson NE; Fan W
Cancer Res; 2007 Jun; 67(11):5337-44. PubMed ID: 17545614
[TBL] [Abstract][Full Text] [Related]
10. Mechanical effects of EB1 on microtubules depend on GTP hydrolysis state and presence of paclitaxel.
Lopez BJ; Valentine MT
Cytoskeleton (Hoboken); 2014 Sep; 71(9):530-41. PubMed ID: 25160006
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of paclitaxel-induced microtubule stabilization, mitotic arrest, and apoptosis by the microtubule-targeting agent EM012.
Zhou J; Liu M; Aneja R; Chandra R; Joshi HC
Biochem Pharmacol; 2004 Dec; 68(12):2435-41. PubMed ID: 15548390
[TBL] [Abstract][Full Text] [Related]
12. Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity.
Tinley TL; Randall-Hlubek DA; Leal RM; Jackson EM; Cessac JW; Quada JC; Hemscheidt TK; Mooberry SL
Cancer Res; 2003 Jun; 63(12):3211-20. PubMed ID: 12810650
[TBL] [Abstract][Full Text] [Related]
13. Regulation of microtubule assembly by human EB1 family proteins.
Bu W; Su LK
Oncogene; 2001 May; 20(25):3185-92. PubMed ID: 11423968
[TBL] [Abstract][Full Text] [Related]
14. Eribulin targets a ch-TOG-dependent directed migration of cancer cells.
Chanez B; Gonçalves A; Badache A; Verdier-Pinard P
Oncotarget; 2015 Dec; 6(39):41667-78. PubMed ID: 26497677
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC
Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832
[No Abstract] [Full Text] [Related]
16. Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway.
Lai TC; Fang CY; Jan YH; Hsieh HL; Yang YF; Liu CY; Chang PM; Hsiao M
Cell Commun Signal; 2020 Oct; 18(1):164. PubMed ID: 33087151
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.
Lopus M; Smiyun G; Miller H; Oroudjev E; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1013-24. PubMed ID: 26416565
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
Zhou Y; Inaba S; Liu J
Int J Oncol; 2006 Jul; 29(1):289-95. PubMed ID: 16773211
[TBL] [Abstract][Full Text] [Related]
19. [Effects of trichostatin A and paclitaxel on apoptosis and microtubule stabilization in endometrial carcinoma cells: an in vitro research].
Jiang SJ; Zhang S; Mu XY; Li W; Wang Y
Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(34):2427-31. PubMed ID: 19087722
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Wang S; Huang X; Lee CK; Liu B
Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
